RegulatoryOfficial

EMA extends 2026/2027 flu vaccine composition advice to mRNA influenza vaccines

🇪🇺 EMA · Tue 17 Nov 2026

The EU regulator's 17 November update adds a recommendation for nucleic acid-based flu vaccines and revises Annex I on reagents for vaccine standardisation.

The European Medicines Agency (EMA) updated its EU recommendations for the composition of 2026/2027 seasonal influenza vaccines on 17 November 2026. The revision adds a recommendation for mRNA (nucleic acid) influenza vaccines. Annex I, which covers reagents for vaccine standardisation, was also updated.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Official source: EMA ↗

Article written by VigiEye from the official source (EMA). AI-assisted; check the source before acting.